

V. Marco Ranieri  
Gordon D. Rubenfeld  
B. Taylor Thompson

## Defining ARDS: do we need a mandatory waiting period?

---

Received: 18 December 2012  
Accepted: 19 December 2012  
Published online: 31 January 2013  
© Springer-Verlag Berlin Heidelberg and ESICM 2013

---

This editorial refers to the article available at  
doi:[10.1007/s00134-012-2803-x](https://doi.org/10.1007/s00134-012-2803-x).

---

V. M. Ranieri (✉)  
Dipartimento di Anestesia e di Medicina degli Stati Critici,  
Azienda Ospedaliera S. Giovanni Battista-Molinette,  
Università di Torino, Corso Dogliotti 14, 10126 Turin, Italy  
e-mail: marco.ranieri@unito.it  
Tel.: +39-11-6334001  
Fax: +39-11-6960448

G. D. Rubenfeld  
Program in Trauma, Emergency, and Critical Care,  
Interdepartmental Division of Critical Care Medicine,  
Sunnybrook Health Sciences Centre, University of Toronto,  
Toronto, ON, Canada

B. T. Thompson  
Pulmonary/Critical Care Unit, Department of Medicine,  
Massachusetts General Hospital, Harvard Medical School,  
Boston, MA, USA

Acute respiratory distress syndrome (ARDS) is a devastating clinical picture known to all clinicians that deal with critically ill patients. We all have in mind the clinical hallmarks that identified the ARDS patients treated in our clinical practice: severe respiratory distress; hypoxemic respiratory failure refractory to O<sub>2</sub> administration; standard chest X-ray showing pulmonary edema that is not the result of congestive heart failure or fluid overload; a silent clinical history for chronic respiratory disease [1]. The need for admitting these patients in an ICU for mechanical ventilation with positive end-expiratory pressure (PEEP) and high inspiratory O<sub>2</sub> fraction (FiO<sub>2</sub>) are the

unquestionable therapeutic guidelines we all have clear in mind when dealing with these patients [1].

The process required to organize the clinical and pathophysiological knowledge of ARDS in a formal framework (i.e., the process of defining ARDS) has always been controversial. In this context, ARDS is not unique. For example, the definition of AIDS changed rapidly as more of the underlying pathogenesis became understood [2]; the definitions of chronic fatigue syndrome [3] and of chronic migraine [4] are controversial. Nevertheless, it is unquestionable that effective and shared definitions are needed by clinicians to guide selection of the most appropriate treatment for the patients that are expected to benefit the most and to optimize use of resources and communication to the relatives by predicting outcome and by clinical scientist to generate consistent and reproducible clinical studies by including patients with a consistent phenotype [5].

In 1994, the first broad consensus was achieved for a definition of ARDS by the American–European Consensus Conference Committee (AECC). Under the auspices of the American Thoracic Society (ATS) and of the European Society of Intensive Care Medicine (ESICM), Gordon Bernard and Antonio Artigas chaired a consensus group that included around 50 experts in the field from North America and Europe. Experts were grouped in subcommittees that met in occasion of the annual meetings of both societies from 1992 (Miami) to 1996 (Glasgow). Bernard, Artigas, and coworkers defined ARDS as the acute onset of hypoxemia (PaO<sub>2</sub>/FiO<sub>2</sub> ≤200 mmHg) with bilateral infiltrates on frontal chest x-ray consistent with edema in the absence of left atrial hypertension. They also defined a new, broader term, Acute Lung Injury (ALI), defined using the same criteria but with a less stringent criterion for hypoxemia (PaO<sub>2</sub>/FiO<sub>2</sub> ≤300 mmHg). Thus, ALI included ARDS, but it also included a subset with relatively mild hypoxemia (i.e., PaO<sub>2</sub>/FiO<sub>2</sub> 201–300). The panel paid particular

attention to the implication of the definition of ARDS for design and coordination of clinical trials [6–9]. The two major advantages of this consensus definition are: (a) including patients with less severe hypoxemia ( $200 < \text{PaO}_2/\text{FiO}_2 \leq 300$  mmHg) may facilitate enrollment in clinical trials and ultimately demonstrate benefit in both the severe and less severe subsets (b) the definition is simple to apply in the clinical setting thus enabling large scale epidemiologic studies [10]. The AECC therefore allowed generation of a large amount of data advancing our knowledge on the incidence and outcomes and improving our ability to better care for patients with ARDS [11, 12].

Despite this unquestionable success, a number of issues regarding the AECC definition have emerged [13, 14]. First, the AECC demanded the “acute onset” but does not explicitly define the time window (e.g., hours, days, or weeks), nor from when to judge the onset of the syndrome. Second, the chest X-ray criterion has been shown to have poor to moderate inter-observer reliability. Third, although the definition requires a pulmonary artery wedge pressure (PAWP)  $\leq 18$  mm Hg (when measured), patients with ARDS frequently have elevated PAWPs often because of transmitted airway pressures and/or vigorous fluid resuscitation. Fourth, there is evidence that ALI and ARDS as defined using the AECC criteria is under-recognized by clinicians, particularly the subgroup of patients with milder hypoxemia (i.e., those with  $\text{PaO}_2/\text{FiO}_2$  201–300) [15]. Fifth,  $\text{PaO}_2/\text{FiO}_2$  is not constant across a range of both  $\text{FiO}_2$  and PEEP in individual patients. In an elegant study of four combinations of  $\text{FiO}_2$  and PEEP with standardized tidal volumes applied 24 h after ARDS onset, Villar and coworkers determined that the combination of PEEP  $> 10$  cm  $\text{H}_2\text{O}$  and  $\text{FiO}_2 > 0.5$  with a tidal volume of 7 ml/kg PBW demonstrated substantial reclassification of high- and low-mortality groups in comparison to  $\text{PaO}_2/\text{FiO}_2$  ratios determined on usual care ventilator settings at the time of diagnosis [16]. They proposed that standardized ventilator settings after a 24 h waiting period should be used to define ARDS [16].

To address these limitations of the AECC definition, the European Society of Intensive Care Medicine, with the endorsement of the American Thoracic Society and of the Society of Critical Care Medicine, convened an international expert panel to revise and adjust the AECC definition of ARDS. Feasibility, reliability, face validity and predictive validity were important considerations in developing the new definition. An empiric evaluation of the preliminary draft using data from more than 4,000 patients with presumed ARDS recruited from several clinical trials and observational cohorts from North America, Europe, and Australia was done to assess predictive validity. A requirement for standardized ventilator settings was considered but not thought to be feasible as this practice is not generally part of contemporary usual

care. The essential aspects of the new definition (the “Berlin definition”) are as follows. First, acute was defined as 1 week or less. Second, chest radiograph criteria were clarified to improve inter-reliability and example radiographs provided. Third, the wedge pressure criterion was removed and clinical vignettes added in an effort to improve the ability to exclude cardiac causes of bilateral infiltrates. Fourth, the term acute lung injury was abandoned. Fifth, measurement of the  $\text{PaO}_2/\text{FiO}_2$  ratio was changed to require a specific minimum amount of PEEP; three categories of ARDS were proposed (mild, moderate, and severe) based on the  $\text{PaO}_2/\text{FiO}_2$  ratio cut-offs of 300 and below [17, 18]. In addition, minute ventilation (as a surrogate for dead space), and compliance of the respiratory system were initially proposed by the consensus panel. Empiric evaluation revealed that inclusion of these variables did not improve the predictive validity and they were therefore removed saving clinicians and clinical scientists from an otherwise much more complicated definition [19, 20].

In this issue of the journal, Villar and coworkers expand on their prior work by demonstrating in a prospective observational cohort ( $n = 282$ ) that the  $\text{PaO}_2/\text{FiO}_2$  ratio obtained on ventilator settings where the  $\text{FiO}_2$  was at least 0.5 with a PEEP of at least 10 cm  $\text{H}_2\text{O}$  24 h of ARDS onset may allow a better risk classification. The  $\text{PaO}_2/\text{FiO}_2$  determined on these settings no later than 24 h after ARDS onset, stratified patients into mild ( $\text{PaO}_2/\text{FiO}_2 > 200$ ;  $n = 47$ , mortality 17 %), moderate ARDS ( $\text{PaO}_2/\text{FiO}_2$  100–200;  $n = 149$ , mortality 40.9 %), and severe ARDS ( $\text{PaO}_2/\text{FiO}_2 < 100$  ( $n = 86$ , mortality 58.1 %) ( $p = 0.00001$ ). They concluded that this definition will allow enrollment of appropriate patients (e.g., higher risk) in therapeutic clinical trials and called this a “universal definition of ARDS” [21]. Unfortunately, a direct statistical comparison of the definitions was not performed.

The standardization of both  $\text{FiO}_2$  and PEEP when using  $\text{PaO}_2/\text{FiO}_2$  to estimate the severity of venous admixture is physiologically sound. However, the prognostic value of the  $\text{PaO}_2/\text{FiO}_2$  ratio on standardized settings 24 h after ARDS onset will reflect the combined effects of disease progression and the standardized settings. As the authors themselves note, “it appears that patients who are getting better early in the course do better, and those that decline over the first 24 h do worse.” We agree and propose that it is better to identify all patients with the syndrome as early as possible. Moreover, as secular trends in ventilator management continue toward the use of lower tidal volumes and higher PEEP, the gap between proposed standardized settings and usual care ventilator practices narrows and the value of standardization diminishes. In a recent evaluation of this issue using a much larger cohort, Britos and colleagues found no change in the predictive validity of  $\text{PaO}_2/\text{FiO}_2$  when PEEP was added [22]. The receiver operator characteristic curve for  $\text{PaO}_2/\text{FiO}_2$  and oxygenation index were surprisingly similar. Greater

standardization of ventilator management in usual care may explain the different observations [22].

The approach advocated by Villar and colleagues would certainly be appropriate for studies of high-risk interventions where the risk to benefit profile may be more acceptable and the anticipated benefits could be expected after a 24-h waiting period. However, most successful interventions in experimental lung injury must be given before or shortly after the insult, and nearly all have failed in clinical trials of established ARDS. Thus, the focus in increasingly on earlier intervention and prevention of ARDS, would not be possible with a 24 h waiting period [23]. Changing the ventilator to standardized settings to determine eligibility for a clinical trial is a research procedure and requires informed consent if such a practice is not part of usual care. This will make large scale epidemiologic studies impossible and biased [24]. This requirement would also make it impossible to study

the clinical recognition of ARDS as clinicians would first have to recognize these patients to place them on the standardized ventilator settings to make the diagnosis. These major limitations make the standardized settings and the mandatory waiting period unsuitable requirements for a “universal” definition, much less a feasible one.

Syndrome definitions should be in a constant state of evolution and debate. Until we have, and to allow us to find, the perfect biomarker for lung injury, investigators must apply standardized definitions using training materials [25]. Investigators are encouraged to apply refinements to the “Berlin Definition” for specific studies that enrich the patient population. In a clinical trial where a 24-h delay in randomization and consent are outweighed by the value of assessing PEEP responsiveness on standardized ventilator settings, the modifications to the Berlin Definitions as proposed by Villar, et al. [21], would be extremely valuable.

## References

- Ashbaugh DG, Bigelow DB, Petty TL, Levine BE (1967) Acute respiratory distress in adults. *Lancet* 2:319–323
- Hall HI, Correa A, Yoon PW, Braden CR (2012) Lexicon, definitions, and conceptual framework for public health surveillance. *MMWR Surveill Summ* 61(Suppl):10–14
- Christley Y, Duffy T, Martin CR (2012) A review of the definitional criteria for chronic fatigue syndrome. *J Eval Clin Pract* 18:25–31
- Torelli P, Manzoni GC (2012) A redefinition of primary headache: chronic migraine. *Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol* 33(Suppl 1):S17–S20
- Rubinfeld GD (2003) Epidemiology of acute lung injury. *Crit Care Med* 31:S276–S284
- Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R (1994) The American–European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 149:818–824
- Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R (1994) Report of the American–European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. *Intensive Care Med* 20:225–232
- Artigas A, Bernard GR, Carlet J, Dreyfuss D, Gattinoni L, Hudson L, Lamy M, Marini JJ, Matthay MA, Pinsky MR, Spragg R, Suter PM (1998) The American–European consensus conference on ARDS, part 2: Ventilatory, pharmacologic, supportive therapy, study design strategies and issues related to recovery and remodeling. *Intensive Care Med* 24:378–398
- Artigas A, Bernard GR, Carlet J, Dreyfuss D, Gattinoni L, Hudson L, Lamy M, Marini JJ, Matthay MA, Pinsky MR, Spragg R, Suter PM (1998) The American–European consensus conference on ARDS, part 2: ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. *Acute respiratory distress syndrome. Am J Respir Crit Care Med* 157:1332–1347
- Ware LB, Matthay MA (2000) The acute respiratory distress syndrome. *New Engl J Med* 342:1334–1349
- Li G, Malinchoc M, Cartin-Ceba R, Venkata CV, Kor DJ, Peters SG, Hubmayr RD, Gajic O (2011) Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota. *Am J Respir Crit Care Med* 183:59–66
- Rubinfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD (2005) Incidence and outcomes of acute lung injury. *New Engl J Med* 353:1685–1693
- Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, Scales DC, Stather DR, Li A, Jones A, Gattas DJ, Hallett D, Tomlinson G, Stewart TE, Ferguson ND (2009) Has mortality from acute respiratory distress syndrome decreased over time? A systematic review. *Am J Respir Crit Care Med* 179:220–227
- Levy MM (2004) PEEP in ARDS—how much is enough? *New Engl J Med* 351:389–391
- Ferguson ND, Frutos-Vivar F, Esteban A, Fernandez-Segoviano P, Aramburu JA, Najera L, Stewart TE (2005) Acute respiratory distress syndrome: underrecognition by clinicians and diagnostic accuracy of three clinical definitions. *Crit Care Med* 33:2228–2234
- Villar J, Perez-Mendez L, Lopez J, Belda J, Blanco J, Saralegui I, Suarez-Sipmann F, Lopez J, Lubillo S, Kacmarek RM (2007) An early PEEP/FIO2 trial identifies different degrees of lung injury in patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 176:795–804
- Ranieri VM, Rubinfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS (2012) Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 307:2526–2533

18. Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, Brochard L, Brower R, Esteban A, Gattinoni L, Rhodes A, Slutsky AS, Vincent JL, Rubenfeld GD, Thompson BT, Ranieri VM (2012) The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. *Intensive Care Med* 38:1573–1582
19. Angus DC (2012) The acute respiratory distress syndrome: what's in a name? *JAMA, J Am Med Assoc* 307:2542–2544
20. Camporota L, Ranieri VM (2012) What's new in the "Berlin" definition of acute respiratory distress syndrome? *Minerva Anestesiol* 78:1162–1166
21. Villar J, Pérez-Méndez L, Blanco J, Añón JM, Blanch L, Belda J, Santos-Bouza A, Fernández RL, Kacmarek RM, Spanish Initiative for Epidemiology, Stratification, and Therapies for ARDS (SIESTA) Network (2013) A universal definition of ARDS: the PaO<sub>2</sub>/FiO<sub>2</sub> ratio under a standard ventilatory setting—a prospective, multicenter validation study. *Intensive Care Med*. doi: [10.1007/s00134-012-2803-x](https://doi.org/10.1007/s00134-012-2803-x)
22. Britos M, Smoot E, Liu KD, Thompson BT, Checkley W, Brower RG (2011) The value of positive end-expiratory pressure and Fio(2) criteria in the definition of the acute respiratory distress syndrome. *Crit Care Med* 39:2025–2030
23. Matthay MA, Thompson BT, Read EJ, McKenna DH Jr, Liu KD, Calfee CS, Lee JW (2010) Therapeutic potential of mesenchymal stem cells for severe acute lung injury. *Chest* 138:965–972
24. Tu JV, Willison DJ, Silver FL, Fang J, Richards JA, Laupacis A, Kapral MK (2004) Impracticability of informed consent in the Registry of the Canadian Stroke Network. *New Engl J Med* 350:1414–1421
25. Ellsworth DL, Manolio TA (1999) The emerging importance of genetics in epidemiologic research II. Issues in study design and gene mapping. *Ann Epidemiol* 9:75–90